Agile Therapeutics's EBITDA per Share for the
three
months ended in Dec. 2023 was $-1.37.
During the past 3 years, the average EBITDA Per Share Growth Rate was 82.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 61.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 37.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Agile Therapeutics was 82.80% per year. The lowest was -5.60% per year. And the median was 16.60% per year.
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agile Therapeutics 3-Year EBITDA Growth Rate Distribution
For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Agile Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Agile Therapeutics 3-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Agile Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Agile Therapeutics (Agile Therapeutics) Business Description
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your